Skip to main content
Smart Investors Daily
AN

NASDAQ · ANIX

Anixa Biosciences, Inc.

Healthcare · Biotechnology

$2.55

Down-$0.07 (-2.67%)

Updated Nov 17, 2026, 5:34 AM

SID Score

3.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
99.47M
P/E ratio
-8.85
Dividend yield
0.00%
52-week range
$2.32 – $5.46
Volume
123.96K
Avg. volume
307.4K

Price performance · ANIX

ANIX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 16, 2026

ANIX closed at $2.55 after 21 trading sessions, down 2.30% for the selected period.

Last close
$2.55
Period change
-2.30%
Period low
$2.55
Period high
$3.37
Daily close
View OHLC price history
ANIX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 16, 2026$2.61$2.6967$2.54$2.55123.96K
Nov 13, 2026$2.71$2.726$2.57$2.62278.67K
Nov 12, 2026$2.72$2.8454$2.66$2.68276.28K
Nov 11, 2026$3.07$3.11$2.77$2.78278.71K
Nov 10, 2026$3.14$3.205$3.04$3.06155.57K
Nov 9, 2026$3.21$3.30$3.0936$3.16128.72K
Nov 6, 2026$3.02$3.18$2.99$3.175121.66K
Nov 5, 2026$3.27$3.27$3.00$3.03201.1K
Nov 4, 2026$3.11$3.32$3.05$3.28218.71K
Nov 3, 2026$3.04$3.19$3.01$3.055149.83K
Nov 2, 2026$3.14$3.1513$2.98$2.99128.34K
Oct 30, 2026$3.28$3.35$3.10$3.12140.66K
Oct 29, 2026$3.40$3.4394$3.28$3.30136.58K
Oct 28, 2026$3.26$3.43$3.20$3.37251.54K
Oct 27, 2026$2.95$3.34$2.945$3.28497.9K
Oct 26, 2026$2.94$2.98$2.89$2.93135.64K
Oct 23, 2026$2.80$3.14$2.74$2.99326.69K
Oct 22, 2026$2.70$2.78$2.68$2.78156.81K
Oct 21, 2026$2.68$2.746$2.655$2.71115.73K
Oct 20, 2026$2.64$2.75$2.64$2.68166.8K
Oct 19, 2026$2.67$2.69$2.60$2.6191.27K

Latest ANIX news

The latest Smart Investors Daily articles mentioning ANIX.

ANIX research

Overview

Company profile and research snapshot.

Company profile

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$5.83
Implied upside
—
Analysts
10
ANIX recent ratings
DateFirmRatingTarget
Sep 22, 2026HC Wainwright & Co.Buy—
Apr 8, 2026D. Boral CapitalBuy—
Mar 31, 2026D. Boral CapitalBuy—
Feb 4, 2026D. Boral CapitalBuy—
Dec 12, 2025D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 4, 2026

Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Robert Wenham, M.D., Chair of the Gynecologic Oncology Program at Moffitt Cancer Center ("Moffitt") and principal investigator of Anixa's ongoing Phase 1 clinical trial evaluating its novel CAR-T therapy for recurrent ovarian cancer, will present at the ESMO (European Society of Medical Oncology) Immuno-Oncology & Advanced Therapies Co

Yahoo · Oct 26, 2026

Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has completed dosing of the fifth cohort in its ongoing Phase 1, dose-escalating, clinical trial (ClinicalTrials.gov NCT05316129) evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer. The study is being conducted at Moffitt Cancer Center ("Moffitt"). The sixth cohort is expected to commence following a routi

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.